Product logins

Find logins to all Clarivate products below.


Alexandr Ishkin, PhD

Principal Consultant for Discovery and Translational Science Consulting

Alex has over 15 years of experience as a science analyst in systems biology and bioinformatics, working with GeneGo and later Thomson Reuters and Clarivate. His key expertise is in network and pathway analysis of high-throughput molecular data sets, such as DNA-Seq, RNA-Seq, single-cell RNA-Seq, gene expression microarray, proteomics and metabolomics, in the context of drug development.
Alex is an expert in Clarivate’s products MetaBaseTM and CDDI. For over 10 years, he has been responsible for development and maintenance of Clarivate’s metabaseR package that enables efficient access to and bioinformatics analyses of the extensive MetaBaseTM content.

Alex is a program manager and principal software developer for two Clarivate-led precompetitive consortia, CBDD and ABC. The CBDD consortium (Computational Biology for Drug Discovery) was launched in 2013. Within the consortium, Alex developed a toolkit of over 70 advanced network analysis algorithms for drug discovery. Consortium members include Novartis, Pfizer, Sanofi, Roche, Merck, Janssen, Takeda, Boehringer Ingelheim, Eli Lilly, BMS, Abbvie, Biogen, UCB, Regeneron, and Daiichi Sankyo. The ABC (Algorithm Benchmarking Consortium) program is centered around benchmarking bioinformatics tools relevant for drug development research and has been running since 2021. Since its inception, the program helped customers to identify best-performing tools and practices across many areas of bioinformatics research.


arrow_forward
Get in touch with Alexandr

Latest news

News May 19, 2026
Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform

New cloud-based, shared platform based on Alma and Primo to help National Library of Technology advance library services and information accessibility London, U.K. May 19, 2026: Clarivate Plc (NYSE:CLVT), a…

News May 13, 2026
Clarivate Identifies Five Medtech Trends Set to Redefine Growth Opportunities in 2026

New Medtech Trends to Watch report highlights market shifts, care delivery changes and competitive dynamics poised to reshape medtech strategy London, U.K.  May 13, 2026. Clarivate Plc (NYSE:CLVT), a leading…

News May 6, 2026
Clarivate launches Web of Science Research Intelligence

AI-native research intelligence platform for research funding, strategy and impact now available globally to institutions LONDON, UK — May 6, 2026: Clarivate Plc (NYSE: CLVT), a leading global provider of…

Related resources

How the Inflation Reduction Act could impact access to more convenient therapeutics How the Inflation Reduction Act could impact access to more convenient therapeutics
Blog February 17, 2026
How the Inflation Reduction Act could impact access to more convenient therapeutics
Biopharma Biotech Commercialization Consulting Resource Center FDA HMO Insurance Launch Managed care Market Access North America Payer Pharma pricing Route of administration U.S.
Managing uncertainty for medicine in Washington Managing uncertainty for medicine in Washington
Blog May 15, 2025
Managing uncertainty for medicine in Washington
Clinical research Early drug development research Market Access Pharma Portfolio strategy Research Research and development Research commercialization Research evaluation and management
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Blog April 2, 2025
Navigating uncertainty: What’s keeping healthcare execs up at night in this new era
Market Access Pharma Portfolio strategy Regulatory Research commercialization
Five Medtech Trends to Watch in 2025 Five Medtech Trends to Watch in 2025
Blog February 11, 2025
Five Medtech Trends to Watch in 2025
Medical technology Medtech Medtech Resource Center